Clinical Trials Browser

Unknown × eribulin × Clear all

NCT06678230 2024-11-07

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT05833919 2023-04-27

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

Phase 2 Unknown

Breast Neoplasms

NCT03613181 2023-04-24

ANGLeD

Phase 3 Unknown

Brain Neoplasms, Breast Neoplasms, Meningeal Neoplasms, Meningeal Carcinomatosis

NCT04303741 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Phase 2 Unknown

Breast Neoplasms

NCT05335473 2023-04-06

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

Phase 1/2 Unknown

HR Positive HER2 Negative Advanced Breast Cancer

NCT05546255 2022-09-19

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT05263882 2022-03-03

Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer

Phase 2 Unknown

HER2-negative Breast Cancer

NCT04913571 2021-06-04

TEMPLATE

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04683445 2020-12-24

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Breast Neoplasms

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT04517292 2020-08-18

GEP

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04502680 2020-08-11

EMBRAVE-001

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT01372579 2019-06-07

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Phase 2 Unknown

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT03925233 2019-04-24

Breast Cancer Treatment Based on Organ-like Culture

Breast Cancer Organoids

NCT03412955 2018-02-27

A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes

Phase 2 Unknown

Breast Neoplasms

NCT03245112 2017-08-16

Halaven Patient Registry (Metastatic Breast Cancer, MBC)

Breast Neoplasms

NCT02175446 2016-06-15

GIM11-BERGI

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

NCT02616848 2015-11-30

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Phase 1 Unknown

Triple Negative Breast Neoplasms